Dr. Rossana Berardi MD
Consultant Medical Oncologist, UNIVERSITA' POLITECNICA DELLE MARCHE
Member of the Healthcare Council
Council Member Biography
Rossana Berardi, MD, is a Consultant Medical Oncologist and Lecturer at University Hospital. She is also responsible for the Trial Unit in the Department of Oncology at the Universita Politecnica delle Marche, Italy. Dr. Berardi usually deals with about 35 GCP trials each year, mainly in lung and GI cancer. She also treats significant numbers of breast and urological cancer patients. Dr. Berardi has been awarded many grants and prizes in research as well as authored many scientific publications and presented at national and international meetings. Dr. Berardi has a special interest in consulting with pharmaceutical companies regarding acquisitions and design of clinical trials. She has been selected as an expert evaluator in several boards of examiners (i.e. European Community). (This is me - Update Profile)
Employment History
- 2005 - Unspecified
- Consultant Medical Oncologist, UNIVERSITA' POLITECNICA DELLE MARCHE
- 2000 - Unspecified
- Lecturer, UNIVERSITA' POLITECNICA DELLE MARCHE
- 1999 - 1999
- Research Fellow, UNIVERSITY COLLEGE LONDON
GLG NewsSM Analyses by Rossana Berardi
GLG News is now G+ Insights
-
G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.
-
Cost will be the tricky point...
August 22, 2009
IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com
I believe that, considering the other available agents, gefitinib could be prescribed to up to 1/3 of NSCLC patients...
-
July 2, 2009
IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com
The approval of Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.
-
Iressa: will it be a new therapeutic option or will it replace another existing option?
May 4, 2009
IRESSA (Gefitinib) Recommended for Approval for the Treatment of Non-Small Cell Lung Cancer in Europe | www.pipelinereview.com
The recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the EMEA recommending to grant a marketing authorisation for Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.
-
Another good result for Roche.
March 23, 2009
UPDATE 1-Roche's Herceptin prolongs stomach cancer survival | www.reuters.com
The results from ToGA, a large international phase III trial, showed the benefit of herceptin plus chemotherapy vs chemotherapy alone as the first therapy for patients with advanced unresectable gastric cancer.
-
A Novel Option for Management of Malignant Ascites.
March 23, 2009
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE: SUMMARY OF POSITIVE OPINION FOR REMOVAB | www.emea.europa.eu
Catumaxomab is a trifunctional monoclonal antibody with 2 antigen-recognition sites: one for human EpCAM, a cell surface antigen expressed by a variety of epithelial tumor cells, and one for human CD3, a T-cell surface antigen. In addition, another region of the antibody binds to receptors that are expressed on other cells of the immune system.
GLG Study Groups with Rossana Berardi(?)
| Study Group Name | No. Members |
|---|---|
| Oncologists (EU) | 788 |
| Physicians who Prescribe Opioids | 680 |
| Oncologists (Germany, France, Italy) | 352 |
| Council Members who Treat Colon/Colorectal Cancer | 274 |
| Physicians who Treat Liver Cancer | 178 |
GLG Live Meetings with Rossana Berardi(?)
Rossana Berardi has not participated in any GLG Live Meetings.
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.